New pill aims to tackle Huntington's at its source

NCT ID NCT07378644

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This clinical trial tests an oral drug called SKY-0515 in 400 adults with Huntington's disease. The goal is to see if it can lower harmful proteins linked to the disease and improve symptoms like movement and thinking. Participants take the drug or a placebo daily for 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SKY-0515 (an oral small molecule drug)

What this could lead to

If successful, this could point toward a treatment that slows or improves Huntington's disease symptoms by lowering harmful proteins in the brain.

What could go wrong

This is an early-to-mid stage trial, so the drug may not work or could have side effects. The results may not apply to all people with Huntington's disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Buenos Aires British Hospital

    RECRUITING

    CABA, Buenos Aires, 1280AEB, Argentina

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • CETRAM (Centro de Trastornos del Movimiento)

    RECRUITING

    Santiago, Santiago Metropolitan, 9120500, Chile

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • CINME Centro de Investigaciones Metabólicas

    RECRUITING

    CABA, Buenos Aires, C1056 AB, Argentina

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-••••

  • Fundación Scherbovsky

    RECRUITING

    Mendoza, Mendoza Province, M5500, Argentina

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Instituto Argentino de Investigación Neurológica

    RECRUITING

    CABA, Buenos Aires, C1015ABR, Argentina

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-••••

  • North York General Hospital

    NOT_YET_RECRUITING

    Toronto, Ontario, M2K 1E1, Canada

    Contact

  • PSEG Centro de Pesquisa Clinica

    RECRUITING

    São Paulo, São Paulo, 04038002, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Pineo Medical Ecosystem

    RECRUITING

    Tbilisi, Georgia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sanatorio Mater Dei

    RECRUITING

    CABA, Buenos Aires, C1425, Argentina

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Simon Khechinashvili University Hospital

    RECRUITING

    Tbilisi, Georgia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact